摘要
20余年来 ,肿瘤的导向治疗研究经历了高潮和低潮的多次反复 ,终于在近几年取得突破性进展 ,以Ritux imab、Tractuzumab和DAB389IL 2为代表的抗肿瘤导向治疗制剂已经通过FDA批准上市 。
Targeting therapy of cancer has been for more than 20 years through devious developmentes. Recently, it received break?through progress. The Food and Drug Administration just approved the Mabs Rituximab, Tractuzumab and the Chimeric toxin DAB389IL?2. These exciting results suggest that Targeting therapy may be applied in human malignant therapy.
出处
《生物技术通讯》
CAS
2001年第1期48-50,59,共4页
Letters in Biotechnology
